New antibody drug enters first human tests for tough cancers

NCT ID NCT06276491

Recruiting now Disease control Sponsor: Xencor, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive the drug, and researchers will monitor for side effects and any tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XmAb541 (a bispecific antibody)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced ovarian, endometrial, or germ cell tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may cause side effects like cytokine release syndrome, and it may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm fallopian tube cancer germ cell tumor Neoplasms, Germ Cell and Embryonal ovarian cancer ovarian germ cell tumor peritoneum cancer testicular cancer testicular germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER GERM CELL TUMOR OVARIAN CANCER OVARIAN GERM CELL TUMOR TESTICULAR GERM CELL TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Herlev Gentofte Hospital
NOT_YET_RECRUITING

Herlev, 2730, Denmark
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Montefiore Einstein Comprehensive Cancer Center
RECRUITING

The Bronx, New York, 10461, United States
OU Health Stephenson Cancer Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Stanford
RECRUITING

Palo Alto, California, 94304, United States
The John Theruer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of California
RECRUITING

San Francisco, California, 94158, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.